Reuters logo
a month ago
BRIEF-Catalyst Biosciences and ISU Abxis complete dosing of first patient cohort in Hemophilia B clinical trial
June 14, 2017 / 12:23 PM / a month ago

BRIEF-Catalyst Biosciences and ISU Abxis complete dosing of first patient cohort in Hemophilia B clinical trial

1 Min Read

June 14 (Reuters) - Catalyst Biosciences Inc

* Catalyst Biosciences and ISU Abxis complete dosing of first patient cohort in Hemophilia B clinical trial

* Says plans to have top line data from in Hemophilia B clinical trial by end of 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below